Recent Updates
Recently added Catalysts

monofluorophosphate dentifrice

Phase 2

Dentinal Hypersensitivity | Small molecule | Other |GSK plc|Last Updated: Mar 26, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment140

FDA Designations

No designations recorded

Clinical trial landscape

monofluorophosphate dentifrice · 2 trials · 2 indications

Phase 2 2
NCT01831817Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal HypersensitivityDentinal Hypersensitivity
COMPLETED140 Analytics
NCT01691560Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal HypersensitivityDentine Hypersensitivity
COMPLETED140 Analytics
PHASE2COMPLETED
Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
Dentinal HypersensitivityUnlock trial analytics
PHASE2COMPLETED
Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
Dentine HypersensitivityUnlock trial analytics

Study Endpoints

Primary Endpoints

Mean Change From Baseline in Schiff Sensitivity Score at Week 4
Baseline and 4 weeks post administration of study treatment

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant did not respond to air stimulation, 1 - participant responded to air stimulus but did not request discontinuation of stimulus, 2 - participant responded to air stimulus and requested discontinuation of stimulus, 3 - participant responded to air stimulus, considered stimulus to be painful and request discontinuation of stimulus.

Mean Change From Baseline in Schiff Sensitivity Score at Week 8
Baseline and 8 weeks post administration of study treatment

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant did not respond to air stimulation, 1 - participant responded to air stimulus but did not request discontinuation of stimulus, 2 - participant responded to air stimulus and requested discontinuation of stimulus, 3 - participant responded to air stimulus, considered stimulus to be painful and request discontinuation of stimulus.

Median Change From Baseline in Tactile Sensitivity at Week 4
Baseline and 4 weeks post administration of study treatment

Response to tactile sensitivity using a Yeaple probe which allowed application of a known force to the dentin surface, starting at 10g and rising in increments of 10g until the tactile threshold or maximum force was reached. The tactile threshold for each tooth was determined by asking the subject whether the sensation caused discomfort. The pressure setting at which the subject gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. At baseline, the maximum force used was 20g; at all subsequent visits, it was 80g.

Median Change From Baseline in Tactile Sensitivity at Week 8
Baseline and 8 weeks post administration of study treatment

Response to tactile sensitivity using a Yeaple probe which allowed application of a known force to the dentin surface, starting at 10g and rising in increments of 10g until the tactile threshold or maximum force was reached. The tactile threshold for each tooth was determined by asking the subject whether the sensation caused discomfort. The pressure setting at which the subject gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth. At baseline, the maximum force used was 20g; at all subsequent visits, it was 80g.

Mean Change From Baseline in Visual Rating Scale Score at Week 4
Baseline and 4 weeks post administration of study treatment

The intensity of response to stimulus will be rated using a 10 point scale where 1 denotes "No Pain" and 10 denotes "Intense Pain".

Mean Change From Baseline in Visual Rating Scale Score at Week 8
Baseline and 8 weeks post administration of study treatment

The intensity of response to stimulus will be rated using a 10 point scale where 1 denotes "No Pain" and 10 denotes "Intense Pain".

Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4
Baseline to 4 weeks post administration of study treatment

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4
Baseline to 4 weeks post administration of study treatment

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8
Baseline to 8 weeks post administration of study treatment

Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8
Baseline to 8 weeks post administration of study treatment

Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale. In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.

Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4
Baseline to 4 weeks post administration of study treatment

Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).

Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8
Baseline to 8 weeks post administration of study treatment

Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).

Secondary Endpoints

Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire Total Score at Week 4
Baseline and 4 weeks post administration of study treatment
Mean Change From Baseline in Dentine Hypersensitivity Experience Questionnaire (DHEQ) Total Score at Week 8
Baseline and 8 weeks post administration of study treatment
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
5% calcium sodium phosphosilicate/ sodium monofluorophosphateEXPERIMENTALDentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
0% calcium sodium phosphosilicate/sodium monofluorophosphateACTIVE_COMPARATORDentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Sodium monofluorophosphateACTIVE_COMPARATORDentifrice containing 1000 ppmF as sodium monofluorophosphate
Sodium fluorideACTIVE_COMPARATORDentifrice containing 1100 ppmF as sodium fluoride
5% calcium sodium phosphosilicate/sodium monofluorophosphateEXPERIMENTALDentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).

Interventions

NameTypeDescription
5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifriceDRUGCalcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifriceDRUGNo calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
Sodium monofluorophosphate dentifriceDRUGSodium monofluorophospate dentifrice (1000 ppm F)
Sodium Fluoride dentifriceDRUGDentifrice containing 1100ppm F as sodium fluoride
0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifriceDRUGDentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study. * Participants will be required to have at least four teeth with facial/cervical erosion, abra...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about monofluorophosphate dentifrice

What is monofluorophosphate dentifrice used for?

Monofluorophosphate dentifrice is an investigational small molecule being studied for the relief of dentine hypersensitivity, also called dentinal hypersensitivity. It is a toothpaste formulation designed to address tooth sensitivity. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.

Who makes monofluorophosphate dentifrice?

Monofluorophosphate dentifrice is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the dentifrice's efficacy in relieving dentinal hypersensitivity.

What phase is monofluorophosphate dentifrice in?

Monofluorophosphate dentifrice is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. Two Phase 2 trials have been completed, each enrolling 140 participants in the United States.

What clinical trials is monofluorophosphate dentifrice in?

Monofluorophosphate dentifrice has been studied in two completed Phase 2 trials: NCT01691560 and NCT01831817. Both were exploratory studies evaluating an occlusion-based dentifrice for relief of dentinal hypersensitivity, enrolling 140 participants each in the United States.

Is monofluorophosphate dentifrice the same as an occlusion-based dentifrice?

Monofluorophosphate dentifrice is being evaluated as an occlusion-based dentifrice in clinical trials. The trials NCT01691560 and NCT01831817 describe the product as an occlusion-based dentifrice, indicating it works by physically blocking dentinal tubules to reduce sensitivity.